Related Experiment Video
Updated: Dec 3, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Survival After Primary Surgery Compared With Neoadjuvant Chemotherapy in Early-stage Ovarian Cancer
Deanna Huffman1, Rodney Wegner2, Amjad Jalil3
1Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, U.S.A.
Background/Aim:
Our study evaluated the survival of women with early-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC) vs. primary debulking surgery (PDS).
Patients And Methods:
We used the 2004-2015 National Cancer Database to identify women with early ovarian cancer treated with multiagent chemotherapy or surgery. Logistic regression was used to identify predictors of NAC. Overall survival estimates were compared using Kaplan-Meier analysis and Cox proportional hazards regression models were used to examine variables.
Results:
In total, 14,627 women were included. The majority (96%) underwent PDS while (4%) underwent NAC. Median survival time was 40 months (95%CI=37.190-47.280, p<0.0001) in the NAC group and 91 months (95%CI=84.4-110.290, p<0.0001) in the PDS group. Five-year overall survival was 36% for the NAC cohort and 65% for the PDS cohort.
Conclusion:
Women treated with neoadjuvant chemotherapy (NAC) had worse overall and 5-year survival. This finding agrees with the accepted convention of reserving NAC for women with advanced, unresectable disease.
Related Concept Videos
Cancer Survival Analysis
Comparing the Survival Analysis of Two or More Groups
Treatment Resistant Cancers

